Exploitation of the HIF axis for cancer therapy

Cancer Biology and Therapy

Volumn 3, Issue 7, 2004, Pages 608-611

  Escuin, Daniel ^a,b   Simons, Jonathan W ^a   Giannakakou, Paraskevi ^a  

^a EMORY UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cancer therapy; HIF 1 inhibitors; HIF 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA INHIBITOR; IBUPROFEN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL HYPOXIA; GENE THERAPY; HUMAN; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 16644399130     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.7.954     Document Type: Review

References (39)

1. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 2002; 111:709-20.
2. Lando D, Peet DJ, German JJ, Whelan DA, WHitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16:1466-71.
3. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184(1):1-16.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
5. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
6. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64:993-8.
7. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 274:32631-7.
8. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res 2000; 60:4873-80.
9. Park JH, Kim TY, Jong HS, Chun YS, Park JW, Lee CT, et al. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1α in gastric cancer cells. Clin Cancer Res 2003; 9:433-40.
10. Brune B, Zhou J. The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1α (HIF-1α). Curr Med Chem 2003; 10:845-55.
11. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia: A mechanism of O2 sensing. J Biol Chem 2000; 275:25130-8.
12. Zhong H, Agani F, Baccala AA, Laughner E, RiosecoCamacho N, Isaacs WB, et al. Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Res 1998; 58:5280-4.
13. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
14. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor- associated macrophages. Am J Pathol 2000; 157:411-21.
15. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003; 23:165-72.
16. Pribluda VS, Gubish Jr ER, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000; 19:173-9.
17. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors α and β. Cancer Res 2002; 62:3691-7.
18. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:363-75.
19. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1α protein. J Biol Chem 2003; 278:7445-52.
20. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62:4316-24.
21. Saito H, Kobayashi S, Uosaki Y, Sato A, Fujimoto K, Miyoshi K, et al. Synthesis and biological evaluation of quinocarcin derivatives. Chem Pharm Bull (Tokyo) 1990; 38:1278-85.
22. Plowman J, Dykes DJ, Narayanan VL, Abbott BJ, Saito H, Hirata T, et al. Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture kand in mice. Cancer Res 1995; 55:862-7.
23. Fuse E, Nishiie H, Kobayashi H, Ikeda S, Saito H, Covey J, et al. Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs. Eur J Drug Metab Pharmacokinet 1997; 22:53-63.
24. Mirsalis JC, Schindler-Horvat J, Hill JR, Green CE, Mitoma C, Tomaszewski JE, et al. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome. Cancer Chemother Pharmacol 2003; 51:193-201.
25. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, et al. The hypoxia-inducible factor-1 α is a negative factor for tumor therapy. Oncogene 2003; 22:3213-20.
26. Richter K, Buchner J. Hsp90: Chaperoning signal transduction. J Cell Physiol 2001; 188:281-90.
27. Gradin K, McGuire J, Wenger RH, Kvietikova I, fhitelaw ML, Toftgard R, et al. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor. Mol Cell Biol 1996; 16:5221-31.
28. Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, et al. Hypoxia-induced activation of HIF-1: Role of HIF-1α-Hsp90 interaction. FEBS Lett 1999; 460:251-6.
29. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. J Biol Chem 2002; 277:29936-44.
30. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62:2478-82.
31. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61:947-54.
32. Hsu HK, Juan SH, Ho PY, Liang YC, Lin CH, Teng CM, et al. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmacol 2003; 66:263-71.
33. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95:516-25.
34. Jones MK, Szabo IL, Kawanaka H, Husain SS, Tarnawski AS. von Hippel Lindau tumor suppressor and HIF-1α: New targets of NSAIDs inhibition of hypoxia-induced angiogenesis. Faseb J 2002; 16:264-6.
35. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin Cancer Res 2003; 9:3150-7.
36. Greco O, Marples B, Joiner MC, Scott SD. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003; 197:312-25.
37. Fulci G, Chiocca EA. Oncolytic viruses for the therapy of brain tumors and other solid malignancies: A review. Front Biosci 2003; 8:e346-60.
38. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22:2065-72.
39. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001; 8:638-45.